NEA Secondary — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Rami Daoud(Executive Officer)Rick Modi(Chief Executive Officer, Board Member)Laura Richman(Executive Officer)Petra Kaufmann(Executive Officer)Robert Aboud(Executive Officer)
Board seatEdward Mathers· per SEC Form D · $45M raise · filed Oct 2025
Co-investorsAtlas VentureEcoR1 CapitalEight Roads VenturesF-Prime Capital PartnersGV (Google Ventures)New Enterprise Associates (NEA)+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.